ArticleMolecular imaging and biology2019
Near-infrared Fluorescence Ocular Imaging (NIRFOI) of Alzheimer's Disease.
Article in Molecular imaging and biology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 36 citations in OpenAlex.
- Detecting Beta-Amyloid Plaque via Low Rank Based Orthogonal Projection and Spatial-Spectrum Detector Using High-Resolution Quantitative Susceptibility Mapping for Preclinical Studies.IEEE transactions on bio-medical engineering · 2026Article
- Mitochondrial dysfunction in Alzheimer's disease: connecting pathophysiology with neuroimaging.Frontiers in aging neuroscience · 2026Review
- Recent Advances in Fluorescent Theranostics for Alzheimer's Disease: A Comprehensive Survey on Design, Synthesis, and Properties.ACS omega · 2024Review
- Eye-tracking paradigms for the assessment of mild cognitive impairment: a systematic review.Frontiers in psychology · 2023Review
- Linking Cognitive Impairment with Amyloid-β Accumulation in Alzheimer's Disease: Insights from Behavioral Tests and FTIR Spectroscopy.Journal of Alzheimer's disease reports · 2023Article
- Recent advancements toward non-invasive imaging of retinal amyloid-beta for early detection of Alzheimer's disease.Neural regeneration research · 2022Article
- Curcumin Scaffold as a Multifunctional Tool for Alzheimer's Disease Research.Molecules (Basel, Switzerland) · 2022Review
- Optical Imaging of Beta-Amyloid Plaques in Alzheimer's Disease.Biosensors · 2021Review
- An insight into theAsian journal of pharmaceutical sciences · 2021Review
- Role of Retinal Amyloid-β in Neurodegenerative Diseases: Overlapping Mechanisms and Emerging Clinical Applications.International journal of molecular sciences · 2021Review
- Ophthalmic Biomarkers for Alzheimer's Disease: A Review.Frontiers in aging neuroscience · 2021Review
- Turn-on chemiluminescence probes and dual-amplification of signal for detection of amyloid beta species in vivo.Nature communications · 2020Article
- Molecular Imaging of Fluorinated Probes for Tau Protein and Amyloid-β Detection.Molecules (Basel, Switzerland) · 2020Review
- Transgenic models for investigating the nervous system: Currently available neurofluorescent reporters and potential neuronal markers.Biochimica et biophysica acta. General subjects · 2020Review
- Crosstalk between Oxidative Stress and Tauopathy.International journal of molecular sciences · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
Abstract
purposeNear-infrared fluorescence (NIRF) imaging has been widely used in preclinical studies; however, its low tissue penetration represents a daunting problem for translational clinical imaging of neurodegenerative diseases. The retina is known as an extension of the central nerve system (CNS), and it is widely considered as a window to the brain. Therefore, the retina can be considered as an alternative organ for investigating neurodegenerative diseases, and an eye represents an ideal NIRF imaging organ, due to its minimal opacity. PROCEDURES: NIRF ocular imaging (NIRFOI), for the first time, was explored for imaging of Alzheimer's disease (AD) via utilizing "smart" fluorescent probes CRANAD-X (X = - 2, - 3, - 30, - 58, and - 102) for amyloid beta (Aβ), and CRANAD-61 for reactive oxygen species (ROS). Mice were intravenously injected the fluorescence dyes and images from the eyes were captured with an IVIS imaging system at different time points.
resultsAll of the tested NIRF probes could be used to differentiate transgenic AD mice and WT mice, and NIRFOI could provide much higher sensitivity for imaging Aβs than NIRF brain imaging did. Our data suggested that NIRFOI could capture the imaging signals from both soluble and insoluble Aβ species. Moreover, we demonstrated that NIRFOI with CRANAD-102 could be used to monitor the therapeutic effects of BACE-1 inhibitor LY2811376. Compared to NIRF brain imaging, NIRFOI provided a larger change of Aβ levels before and after LY2811376 treatment. In addition, we demonstrated that CRANAD-61 could be used to image reactive oxygen species in the eyes.
conclusionThe large detection margin by NIRFOI is very important for both diagnosis and therapy response monitoring. Compared to fluorescence microscopic imaging, NIRFOI captures signals with a wide angle (large field of view (FOV)) and can be used to detect soluble Aβs. We believe that NIRFOI has remarkable translational potential for future human studies and can be a potential imaging technology for fast, cheap, accessible, and reliable screening of AD in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.